Loading Events

« All Events

  • This event has passed.

Innovation and Biomarkers in Cancer Drug Development (IBCD) 2016

September 8, 2016 - September 9, 2016

Never before has cancer drug and biomarker development been so complex and required such a diverse range of expertise, and IBCD 2016 will help forge the collaborations needed for developing improved treatments for patients with cancer. The intention is to shine a spotlight on multi-stakeholder approaches to cancer drug development with new cancer biomarkers in a scientific program which includes input from regulators, industry, academia, patients, and payers.

The combined efforts of the European Organisation for Research and Treatment of Cancer (EORTC), an academic research organization, the US National Cancer Institute (NCI), a governmental institution, the European Medicines Agency (EMA), a regulatory agency, and the American Association for Cancer Research (AACR), a professional scientific association; have resulted in a unique program:

  • SESSION 1: QA & QC from pre analytical steps to clinical utility
  • SESSION 2: Considerations in assay development and its integration into drug development: Clinical trials and beyond into clinical practice
  • SESSION 3: Patient access and regulatory challenges for clinical trials in the era of molecularly defined “Personalized therapies”
  • SESSION 4: Bioinformatic approaches to big data analysis and the clinical decision process
  • SESSION 5: DEBATE: Impact on health care systems, a multi stakeholder societal challenge for research, pharma and patients
  • SESSION 6: Horizons: Biomarker Signatures Beyond NGS. A bird’s-eye-view of the future of biomarkers on guiding drug development

Website: http://www.eortc.org/ibcd/

Details

Start:
September 8, 2016
End:
September 9, 2016

Venue

Square Brussels Meeting Centre
Brussels, Belgium
+ Google Map
Website:
http://www.squarebrussels.com/